Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 4/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942092 | 0.92 | KCNQ3 (0.42) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL939568 | 0.90 | DGAT1 (0.41) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL940454 | 0.90 | ECE1 (0.43) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL939916 | 0.90 | DGAT1 (0.41) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL941139 | 0.90 | DGAT1 (0.42) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL2894989 | 0.90 | KCNQ3 (0.47) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL939548 | 0.90 | ECE1 (0.42) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL939576 | 0.90 | ECE1 (0.42) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL2900980 | 0.89 | DGAT1 (0.42) | ABCB1DGAT1KCNQ3KCNQ2NPC1 | |
| SCHEMBL2893134 | 0.88 | KCNQ3 (0.49) | ABCB1DGAT1KCNQ3KCNQ2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102143956-B | Derivatives of indole-2-carboxamides and azaindole-2-carboxamides substituted by silane groups, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2014-04-23 | — | — | CN | claimed |
| US-8399491-B2 | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-19 | — | — | US | claimed |
| EP-2235003-B1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-12-19 | — | — | EP | claimed |
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| CN-102143956-B | Derivatives of indole-2-carboxamides and azaindole-2-carboxamides substituted by silane groups, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2014-04-23 | — | — | CN | disclosed |
| US-8399491-B2 | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| EP-2235003-B1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-12-19 | — | — | EP | disclosed |
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| EP-2235003-A1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009109710-A1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009365-A1 | DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, INMT, IDO1 | ABCB1 2489/4885DGAT1 3737/4885KCNQ3 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.